Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs

Current Pharmaceutical Design

Volumn 10, Issue 26, 2004, Pages 3285-3295

  Mitchison, Denis A ^a   Coates, Anthony R M ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Dormacy; Oxygen deficiency; Rifampicin tolerance; Sterilizing

Indexed keywords

CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; BACTERIAL GROWTH; BACTERIUM COLONY; BACTERIUM CULTURE; CULTURE MEDIUM; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IN VITRO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERSISTENT INFECTION; PREDICTION; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GREAT BRITAIN; HUMANS; MODELS, THEORETICAL; MYCOBACTERIUM TUBERCULOSIS; STERILIZATION;

EID: 4644352952     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383269     Document Type: Review

References (46)

1. Bigger JW. Treatment of staphylococcal infections with penicillin. Lancet 1944; ii: 497-500.
2. Canetti G. The tubercle bacillus in the pulmonary lesion of man. New York, Springer 1955; 15-17.
3. Grosser J. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob Agents Chemother 2003; 47: 833-36.
4. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Am Rev Respir Dis 1989; 139: 871-76.
5. Aber VR, Nunn AJ. Factors affecting relapse following short-course chemotherapy. Bull Int Un Tuberc 1978; 53: 260-64.
6. Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993; 147: 1062-3.
7. Mitchison DA. Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease. J Appl Bacteriol Symposium Supplement 1996; 81: 72S-80S.
8. Mitchison DA. Basic mechanisms of chemotherapy. Chest 1980; 76S: 771-81S.
9. Bartmann K, Freise G. Mikrobiologisch bestimmte Isoniazid-Konzentrationen in Gewebe von Tier und Mensch. Beiträge zur Klinik er Tuberkulose 1963; 127: 546-60.
10. Canetti G, Grumbach F. Diffusion de a streptomycine dans les lesions caséeuses des tuberculeux pulmonaires. Annales de l'Institut Pasteur 1953, 85: 380-6.
11. Canetti G, Parrot R, PorvenG, Le Lirzin M. Les taux de rifampicine dans le poumon et dans les lésions tuberculeuses de l'homme. Acta Tuberculosea et Pneumologica Belgica 1969; 3: 315-22.
12. Dhillon J, Mitchison DA. Influence of BCG-induced immunity on the bactericidal activity of isoniazid and rifampicin in experimental tuberculosis of the mouse and guinea-pig. Brit J Exp Path 1989; 70: 103-10.
13. Wallis RS, Song H-Y, Whalen C, Okwera A. Potential antagonism between immunity and sterilization during TB chemotherapy. Am J Respir Crit Care Med. In press.
14. Brindle R, Odhiambo J, Mitchison D. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med 2001; 1: 2.
15. Wallis RS, Vinhas SA, Johnson JL, Ribeiro FC, Palaci M, Peres RL, et al. Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J Infect Dis 2003; 187: 270-8.
16. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996; 64: 2062-9.
17. Wayne LG, Lin K-Y. Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect Immun 1982; 37: 1042-9.
18. Zhang Y, Telenti A. Genetics of drug resistance in Mycobacterium tuberculosis. In: Molecular Genetics of Mycobacteria. Eds: Hatfull GF, Jacobs WR, ASM Press, Washington DC, 2000; 235-54.
19. Dickinson JM, Mitchison DA. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Amer Rev Resp Dis 1981; 123: 367-71.
20. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003; 7: 6-21.
21. Jindani, A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121: 939-49.
22. Mitchison DA, Sturm WA. The measurement of early bactericidal activity. In: Bailliere's Clinical Infectious Diseases: Mycobacterial Diseases Part II, Ed A Malin & KPWJ McAdam. London, Bailliere Tindall 1997; 185-206.
23. Jindani A, Doré CJ, Mitchison DA. The bactericidal and sterilising activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003; 167: 1348-54.
24. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000; 4: 796-806.
25. Donald PR, Sirgel FA, Botha FJ, Seifart HI, Parkin DP, Vandenplas ML et al. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med 1997; 156: 895-900.
26. Hobby GL, Lenert TF. The in vitro action of antituberculous agents against multiplying and non-multiplying microbial cells. Am Rev Tuberc Pulm Dis 1957; 76: 1031-48.
27. Schaefer WB. The effect of isoniazid on growing and resting tubercle bacilli. Amer Rev Tuberc 1954; 69: 125-7.
28. Mitchison DA, Selkon JB. The bactericidal activities of antituberculous drugs. Amer Rev Tuberc 1956; 74: 109-16.
29. Hu Y, Mangan JA, Dhillon J, Sole KM, Mitchison DA, Butcher PD, et al. Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J Bacteriol 2000; 182: 6358-65.
30. Meynell GG, Meynell E. Quantitative aspects. In: Theory and practice in experimental bacteriology. Cambridge University Press 1965; 205-28.
31. Fisher RA, Yates F. Table VIII2. Densities of organisms estimated by the dilution method (W.L. Stevens). In: Statistical tables for biological, agricultural and medical research. Sixth edition. Edinburgh, Oliver and Boyd 1963; 66.
32. Lee JJ, Suo J, Lin CB, Wang JD, Lin TY, Tsen YC. Comparative evaluation of the Bactec MGIT 960 system with solid medium for isolation of mycobacteria. Int J Tuberc Lung Dis 2003; 7: 569-74.
33. Somoskovi A, Magyar P. Comparison of the mycobacteria growth indicator tube with MB redox, Lowenstein-Jensen, and Middlebrook 7H11 media for recovery of mycobacteria in clinical specimens. J Clin Microbiol 1999; 37: 1366-9.
34. McCune R, Tompsett R, McDermott W. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 1956; 104: 763-803.
35. Dhillon J, Allen BW, Hu Y-M, Coates ARM, Mitchison DA. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int J Tuberc Lung Dis 1998; 2: 736-42.
36. Mitchison DA. The Garrod Lecture. Understanding the chemotherapy of tuberculosis - current problems. J Antimicrob Chemother 1992; 29: 477-93.
37. Herbert D, Paramasivan CN, Venkatesan P, Kubendiran G, Prabhakar R, Mitchison DA. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40: 2296-9.
38. Hu Y, Coates ARM. Increased levels of sigJ mRNA in late stationary phase cultures of Mycobacterium tuberculosis detected by DNA array hybridisation. FEMS Microbiol Lett 2001; 202: 59-65.
39. Hu Y, Coates ARM, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 653-7.
40. Coates A, Hu Y, Bax R, Page C. The future challenges facing the development of new antimicrobial drugs. Nature Reviews 2002; 1: 895-910.
41. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000, 405: 962-6.
42. Global Alliance for Tuberculosis Drug Development. Tuberculosis Scientific Blueprint for TB Drug Development. Tuberculosis 2001; 81, Suppl.1: 1-52.
43. Mitchison DA. The search for new sterilizing anti-tuberculosis drugs. Frontiers in Bioscience 2004; 9: 1059-1072.
44. Blake GM, Fogelman I. The role of bone density measurements in the evaluation of new treatments for osteoporosis. Curr Pharm Design 2002; 8(21): 1885-1905.
45. Lankelma J. Tissue transport of anti-cancer drugs. Curr Pharm Design 2002; 8(22): 1987-93.
46. Yanagihara K. Design of anti-bacterial drug and anti-mycobacterial drug for drug delivery system. Curr Pharm Design 2002; 8(6): 475-82.